
This article was originally published on Microdose and appears here with permission.
MindMed ended its 2021 news cycle on a somewhat mehhh note. In late December we reported that the FDA has put a hold on MindMed’s submission for its Phase 2b trial of LSD for the treatment of generalized anxiety disorder.